These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1050 related items for PubMed ID: 9420887

  • 1. Interleukin-12 synergizes with interleukin-2 to generate lymphokine-activated killer activity in peripheral blood mononuclear cells cultured in ovarian cancer ascitic fluid.
    Barton DP, Blanchard DK, Duan C, Roberts WS, Cavanagh D, DeCesare S, Djeu JY.
    J Soc Gynecol Investig; 1995; 2(6):762-71. PubMed ID: 9420887
    [Abstract] [Full Text] [Related]

  • 2. IL-12 synergizes with IL-2 to induce lymphokine-activated cytotoxicity and perforin and granzyme gene expression in fresh human NK cells.
    DeBlaker-Hohe DF, Yamauchi A, Yu CR, Horvath-Arcidiacono JA, Bloom ET.
    Cell Immunol; 1995 Oct 01; 165(1):33-43. PubMed ID: 7671323
    [Abstract] [Full Text] [Related]

  • 3. Interleukin 15 induction of lymphokine-activated killer cell function against autologous tumor cells in melanoma patient lymphocytes by a CD18-dependent, perforin-related mechanism.
    Gamero AM, Ussery D, Reintgen DS, Puleo CA, Djeu JY.
    Cancer Res; 1995 Nov 01; 55(21):4988-94. PubMed ID: 7585540
    [Abstract] [Full Text] [Related]

  • 4. Regulation of lymphokine-activated killer activity and pore-forming protein gene expression in human peripheral blood CD8+ T lymphocytes. Inhibition by transforming growth factor-beta.
    Smyth MJ, Strobl SL, Young HA, Ortaldo JR, Ochoa AC.
    J Immunol; 1991 May 15; 146(10):3289-97. PubMed ID: 1827481
    [Abstract] [Full Text] [Related]

  • 5. Perforin-mediated lysis of tumor cells by Mycobacterium bovis Bacillus Calmette-Guérin-activated killer cells.
    Brandau S, Suttmann H, Riemensberger J, Seitzer U, Arnold J, Durek C, Jocham D, Flad HD, Böhle A.
    Clin Cancer Res; 2000 Sep 15; 6(9):3729-38. PubMed ID: 10999767
    [Abstract] [Full Text] [Related]

  • 6. IL-12 and IL-2 potentiate the in vitro tumor-specific activity of peripheral blood cells from cervical cancer patients.
    Verma V, Sharma V, Shrivastava SK, Nadkarni JJ.
    J Exp Clin Cancer Res; 2000 Sep 15; 19(3):367-74. PubMed ID: 11144531
    [Abstract] [Full Text] [Related]

  • 7. Protein A potentiates lymphokine-activated killer cell induction in normal and melanoma patient lymphocytes.
    Singh KP, Shau H, Gupta RK, Kopald K, Ray PK.
    Immunopharmacol Immunotoxicol; 1992 Sep 15; 14(1-2):73-103. PubMed ID: 1597662
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. On the relative roles of interleukin-2 and interleukin-10 in the generation of lymphokine-activated killer cell activity.
    Spagnoli GC, Juretic A, Schultz-Thater E, Dellabona P, Filgueira L, Hörig H, Zuber M, Garotta G, Heberer M.
    Cell Immunol; 1993 Feb 15; 146(2):391-405. PubMed ID: 8174177
    [Abstract] [Full Text] [Related]

  • 10. Generation of human lymphokine-activated killer cells following an IL-2 pulse in elderly cancer patients.
    Provinciali M, Di Stefano G, Stronati S, Fabris N.
    Cytokine; 1998 Feb 15; 10(2):132-9. PubMed ID: 9512903
    [Abstract] [Full Text] [Related]

  • 11. Generation of human lymphokine-activated killer cells following brief exposure to high dose interleukin 2.
    Horton SA, Oldham RK, Yannelli JR.
    Cancer Res; 1990 Mar 15; 50(6):1686-92. PubMed ID: 2306722
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Lymphokine-activated killer (LAK) cell generation from peripheral blood stem cells by in vitro incubation with low-dose interleukin-2 plus granulocyte-macrophage colony-stimulating factor.
    Herrera C, García-Pérez MJ, Ramirez R, Martín C, Alvarez MA, Martinez F, Gómez P, García-Castellano JM, Torres A.
    Bone Marrow Transplant; 1997 Mar 15; 19(6):545-51. PubMed ID: 9085733
    [Abstract] [Full Text] [Related]

  • 14. IL-2 and IL-6 synergize to augment the pore-forming protein gene expression and cytotoxic potential of human peripheral blood T cells.
    Smyth MJ, Ortaldo JR, Bere W, Yagita H, Okumura K, Young HA.
    J Immunol; 1990 Aug 15; 145(4):1159-66. PubMed ID: 2143209
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Sensitivity of ovarian tumor cells to effector cells generated by various biological response modifiers.
    Nio Y, Zighelboim J, Berek JS, Bonavida B.
    Nat Immun Cell Growth Regul; 1990 Aug 15; 9(4):283-96. PubMed ID: 2215516
    [Abstract] [Full Text] [Related]

  • 17. Activated alpha 2-macroglobulin reverses the immunosuppressive activity in human breast cancer cell-conditioned medium by selectively neutralizing transforming growth factor-beta in the presence of interleukin-2.
    Harthun NL, Weaver AM, Brinckerhoff LH, Deacon DH, Gonias SL, Slingluff CL.
    J Immunother; 1998 Mar 15; 21(2):85-94. PubMed ID: 9551359
    [Abstract] [Full Text] [Related]

  • 18. Inhibition of lymphokine-activated killer cells generation in vitro by soluble factors released from mixed human tumor and peripheral blood mononuclear adherent cells culture.
    Eisenthal A, Barbarsteyn E, Gitstein G, Lifschitz-Mercer B.
    Cancer Invest; 2006 Feb 15; 24(1):28-34. PubMed ID: 16466989
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 53.